BioXcel Therapeutics ($BTAI) $9.75M Investor Settlement
BioXcel Therapeutics has agreed to settle $9,75M with $BTAI investors to resolve claims that it misled them about internal controls, protocol adherence, and data integrity in its Phase 3 TRANQUILITY II clinical trial.
Outline:
In December 2021, BioXcel launched its Phase 3 TRANQUILITY II trial for BXCL501 in Alzheimer’s-related agitation and projected a 2023 data readout. In June 2023, the company disclosed that an FDA inspection found protocol violations at a key trial site and that a principal investigator fabricated safety-report emails. Following the disclosure, $BTAI fell 63.8%, and investors sued. In January 2026, BioXcel agreed to settle for $9,750,000.
Timeline:
December 15, 2021: BioXcel announces initiation of its Phase 3 TRANQUILITY II and III trials for BXCL501 in Alzheimer’s-related agitation.
December 2022: The FDA inspects a TRANQUILITY II trial site and issues a Form 483 citing inspectional observations.
March 9, 2023: BioXcel reports that TRANQUILITY II is fully enrolled and expects top-line data in Q2 2023.
June 29, 2023: BioXcel discloses protocol violations and fabricated email correspondence; shares fall about 63.8%.
July 7, 2023: A securities class action complaint is filed in the District of Connecticut.
February 27, 2026: The parties reach an agreement to settle for $9,75M
Background:
BioXcel Therapeutics is a biopharmaceutical company developing neuroscience and immuno-oncology treatments. One of its lead programs, BXCL501, is a sublingual film formulation under development for agitation associated with Alzheimer’s disease.
Beginning in late 2021, BioXcel advanced its Phase 3 TRANQUILITY II trial and highlighted expected 2023 top-line data, along with BXCL501’s Breakthrough Therapy and Fast Track designations. The company positioned the drug as a potential treatment for a large and growing Alzheimer’s-related agitation market.
In June 2023, BioXcel disclosed that an FDA inspection at a key TRANQUILITY II site identified failures to follow informed consent procedures, maintain adequate case histories, and properly report a serious adverse event. The company also confirmed that a principal investigator fabricated email correspondence that had been provided to regulators.
Following this disclosure, $BTAI declined approximately 63.8% in a single trading day. Investors later filed a securities lawsuit alleging that the company’s statements about trial oversight and data integrity were misleading.
What Can Investors Expect Now?
BioXcel Therapeutics has agreed to settle $9,750,000 with $BTAI investors to resolve claims that it misled them about internal controls, protocol adherence, and data integrity in its Phase 3 TRANQUILITY II clinical trial.
If you were damaged due to this situation, you may be able to file for a payout and receive your share of the settlement. You can review eligibility details in the settlement notice.
Frequently Asked Questions
All Persons that purchased or otherwise acquired BioXcel publicly traded securities from March 9, 2023 through June 28, 2023, inclusive, and were damaged thereby.
No, if you have purchased securities within the class period, you are eligible to participate.
You can participate in the settlement and retain (or sell) your securities.
The entire process usually takes 4 to 9 months after the claim deadline. But the exact timing depends on the court and settlement administration.
The final payout amount depends on your specific trades and the number of investors participating in the settlement.
If 100% of investors file their claims - the average payout will be $1.52 per share. Although typically only 25% of investors file claims, in this case, the average recovery will be $6.08 per share.
If you're eligible, you can file your claim directly from this case page by clicking the "Collect Payout" button.
More than 100 companies are currently paying out settlements. Connect your brokerage account to automatically check which ones you may have missed — or file manually for this case.
11th.com is an investor recovery company that helps investors track and collect securities class action settlements. We will:
1. Prepare documents for your payout.
2. Audit the claim and make sure you get the maximum possible payout.
3. File a claim with the settlement administration.
4. Correspond with the settlement administration to resolve emerging issues.
5. Deliver payout directly to your brokerage account.
There is no upfront cost, but we will deduct 20% of the recovered amount as a commission for our services.